Biosensors based detection of novel biomarkers associated with COVID-19: Current progress and future promise

被引：2

作者：

Pal M. ^{[1
,2
]}

Muinao T. ^{[1
]}

Parihar A. ^{[3
]}

Roy D.K. ^{[4
]}

Boruah H.P.D. ^{[1
,5
]}

Mahindroo N. ^{[6
]}

Khan R. ^{[3
]}

机构：

[1] Biotechnology Group, Biological Sciences and Technology Division, CSIR-North East Institute of Science and Technology (NEIST), Academy of Scientific & Innovative Research (AcSIR), CSIR-NEIST Campus, Assam, Jorhat

[2] Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Punjab, Bathinda

[3] CSIR-Advanced Materials and Processes Research Institute (AMPRI), Hoshangabad Road, MP, Bhopal

[4] Department of Pharmaceutical Technology, JIS University, Kolkata

[5] Government Model College, Kaziranga, Assam, Golaghat

[6] School of Pharmacy, Dr. Vishwanath Karad MIT World Peace University, Maharashtra, Pune

来源：

Biosensors and Bioelectronics: X | 2022年 / 12卷

关键词：

Biosensors; COVID-19; Future challenges; Novel biomarkers; Rapid detection; Risk factors;

D O I：

10.1016/j.biosx.2022.100281

中图分类号：

学科分类号：

摘要：

The pandemic situation of COVID-19 has caused global alarm in health care, devastating loss of lives, strangled economy, and paralysis of normal livelihood. The high inter-individual transmission rate created havoc in the global community. Although tremendous efforts are pitching in from across the globe to understand this disease, the clinical features seemed to have a wide range including fever, cough, and fatigue are the prominent features. Congestion, rhinorrhea, sore throat, and diarrhea are other less common features observed. The challenge of this disease lies in the difficulty in maneuvering the clinical course causing severe complications. One of the major causative factors for multi-organ failure in patients with severe COVID-19 complications is systemic vasculitis and cytokine-mediated coagulation disorders. Hence, effective markers trailing the disease severity and disease prognosis are urgently required for prompt medical treatment. In this review article, we have emphasized currently identified inflammatory, hematological, immunological, and biochemical biomarkers of COVID-19. We also discussed currently available biosensors for the detection of COVID-19-associated biomarkers & risk factors and the detection methods as well as their performances. These could be effective tools for rapid and more promising diagnoses in the current pandemic situation. Effective biomarkers and their rapid, scalable, & sensitive detection might be beneficial for the prevention of serious complications and the clinical management of the disease. © 2022 The Authors

引用

共 141 条

[11]

Chan J.F.W., Yuan S., Kok K.H., To K.K.W., Chu H., Yang J., Xing F., Liu J., Yip C.C.Y., Poon R.W.S., Tsoi H.W., Lo S.K.F., Chan K.H., Poon V.K.M., Chan W.M., Ip J.D., Cai J.P., Cheng V.C.C., Chen H., Hui C.K.M., Yuen K.Y., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster, Lancet, 395, pp. 514-523, (2020)

[12]

Chen C., Gopinath S.C.B., Anbu P., Longitudinal zeolite-iron oxide nanocomposite deposited capacitance biosensor for interleukin-3 in sepsis detection, Nanoscale Res. Lett., 16, (2021)

[13]

Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, 395, pp. 507-513, (2020)

[14]

Chen T., Wu D., Chen H., Yan W., Yang D., Chen G., Ma K., Xu D., Yu H., Wang H., Wang T., Guo W., Chen J., Ding C., Zhang X., Huang J., Han M., Li S., Luo X., Zhao J., Ning Q., Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ, 368, (2020)

[15]

Cheng A., Zhang W., Xie Y., Jiang W., Arnold E., Sarafianos S.G., Ding J., Expression, purification, and characterization of SARS coronavirus RNA polymerase, Virology, 335, pp. 165-176, (2005)

[16]

Cheng Y., Luo R., Wang K., Zhang M., Wang Z., Dong L., Li J., Yao Y., Ge S., Xu G., Kidney disease is associated with in-hospital death of patients with COVID-19, Kidney Int., 97, pp. 829-838, (2020)

[17]

Cleland D.A., Eranki A.P., Procalcitonin, StatPearls [Internet]. Treasure Island (FL), (2021)

[18]

Corman V.M., Landt O., Kaiser M., Molenkamp R., Meijer A., Chu D.K.W., Bleicker T., Brunink S., Schneider J., Schmidt M.L., Mulders D.G.J.C., Haagmans B.L., Van Der Veer B., Van Den Brink S., Wijsman L., Goderski G., Romette J.L., Ellis J., Zambon M., Peiris M., Goossens H., Reusken C., Koopmans M.P.G., Drosten C., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill., 25, (2020)

[19]

Cossarizza A., De Biasi S., Guaraldi G., Girardis M., Mussini C., SARS-CoV-2, the virus that causes COVID-19: cytometry and the new challenge for global health, Cytometry, 97, pp. 340-343, (2020)

[20]

Cui M., Che Z., Gong Y., Li T., Hu W., Wang S., A graphdiyne-based protein molecularly imprinted biosensor for highly sensitive human C-reactive protein detection in human serum, Chem. Eng. J., 431, (2022)

← 1 2 3 4 5 6 7 8 9 10 →